Japan Digestive Disease Week 2025
International Poster Session11 (JDDW)
October 31, 14:00–14:32, Room 15 (Kobe International Exhibition Hall No.1 Building Digital Poster Venue)
IP-51_G
GLP-1 Receptor Agonists and Risk of Intestinal Complications in Patients with Concurrent Inflammatory Bowel Disease and Diabetes: A Retrospective Study Using TriNetX Data
- 1
- Department of Gastroenterology and Hepatology, Chi Mei Medical Center
Introduction
Inflammatory bowel disease (IBD) often coexists with diabetes mellitus (DM), complicating clinical management. GLP-1 receptor agonists (GLP-1RAs) may offer benefits through anti-inflammatory effects, but concerns remain regarding potential gastrointestinal risks such as ileus. This study compared outcomes of GLP-1RAs versus non-GLP-1 oral antidiabetics in patients with IBD and DM.
Methods
Using the TriNetX database, a retrospective cohort study included IBD patients aged over 18 years with type 2 diabetes, excluding prior colectomy cases. After propensity score matching, 1,075 patients per group were compared over 5 years. Primary outcomes were ileus/intestinal obstruction, colectomy, and acute pancreatitis.
Results
No significant differences were observed in ileus/intestinal obstruction (HR: 0.971, 95% CI: 0.713-1.323), colectomy risk (HR: 1.409, 95% CI: 0.684-2.905), or acute pancreatitis (HR: 0.650, 95% CI: 0.384-1.100).
Discussion
GLP-1RA use showed comparable safety to non-GLP-1 medications, but potential gastrointestinal risks merit caution. Prospective studies are needed to clarify GLP-1RA safety in this patient population.
Inflammatory bowel disease (IBD) often coexists with diabetes mellitus (DM), complicating clinical management. GLP-1 receptor agonists (GLP-1RAs) may offer benefits through anti-inflammatory effects, but concerns remain regarding potential gastrointestinal risks such as ileus. This study compared outcomes of GLP-1RAs versus non-GLP-1 oral antidiabetics in patients with IBD and DM.
Methods
Using the TriNetX database, a retrospective cohort study included IBD patients aged over 18 years with type 2 diabetes, excluding prior colectomy cases. After propensity score matching, 1,075 patients per group were compared over 5 years. Primary outcomes were ileus/intestinal obstruction, colectomy, and acute pancreatitis.
Results
No significant differences were observed in ileus/intestinal obstruction (HR: 0.971, 95% CI: 0.713-1.323), colectomy risk (HR: 1.409, 95% CI: 0.684-2.905), or acute pancreatitis (HR: 0.650, 95% CI: 0.384-1.100).
Discussion
GLP-1RA use showed comparable safety to non-GLP-1 medications, but potential gastrointestinal risks merit caution. Prospective studies are needed to clarify GLP-1RA safety in this patient population.
As no diagrams are provided here, please refer to each academic journal of structure and member societies.
- Index Term 1: Inflammatory bowel disease
- Index Term 2: GLP-1 receptor agonists